Illumina, Inc. Acquires EPICENTRE Biotechnologies, Leading Provider of Nucleic Acid Sample Preparation Reagents and Specialty Enzymes

(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) today announced that it has acquired Epicentre Biotechnologies, a leading provider of nucleic acid sample preparation reagents and specialty enzymes used in sequencing and microarray applications. A key component of the acquisition is direct access to Epicentre’s proprietary Nextera™ technology for next-generation sequencing library preparation, which greatly simplifies genetic analysis workflows and reduces time from sample preparation to answer.